论文部分内容阅读
目的:观察扶正化瘀胶囊治疗血吸虫病肝硬化临床疗效。方法:68例患者随机分为2组。治疗组36例,口服扶正化瘀胶囊;对照组32例,口服甘利欣胶囊、肌苷片治疗。2组疗程均为6月。观察治疗前后患者临床疗效、总胆红素(TBi L)、直接胆红素(DBi L)、谷丙转氨酶(ALT)、谷草转氨酶(AST)、血清透明质酸(HA)、Ⅲ型前胶原(PCⅢ)、层黏连蛋白(LN)、IV型胶原(L-IV)的变化。结果:总有效率治疗组86.1%,对照组81.3%,2组比较,差异无统计学意义(P>0.05)。治疗6月后,治疗组和对照组ALT、AST、GGT、TBi L均明显好转,治疗前后比较,差异有统计学意义(P<0.05);2组治疗后比较,差异无统计学意义(P>0.05)。治疗组治疗后血清肝纤维化指标HA、LN、PCⅢ、Ⅳ-C均较治疗前显著降低(P<0.05)。治疗后2组比较,差异有统计学意义(P<0.05)。结论:扶正化瘀胶囊不仅能改善血吸虫病肝硬化患者的临床症状、体征与恢复肝功能,还能有效改善肝纤维化。
Objective: To observe the clinical effect of Fuzheng Huayu capsule on schistosomiasis cirrhosis. Methods: Sixty-eight patients were randomly divided into two groups. Treatment group 36 cases, oral administration of Fuzhenghuayu capsule; control group of 32 cases, oral Gan Lixin capsule, inosine tablets treatment. 2 groups of treatment are June. The clinical efficacy, TBi L, DBi L, ALT, AST, HA, procollagen type Ⅲ were observed before and after treatment. (PC Ⅲ), laminin (LN) and type IV collagen (L-IV). Results: The total effective rate was 86.1% in the treatment group and 81.3% in the control group. There was no significant difference between the two groups (P> 0.05). The levels of ALT, AST, GGT and TBi L in the treatment group and the control group were significantly improved after 6 months of treatment, with significant difference before and after treatment (P <0.05). There was no significant difference in the two groups after treatment (P > 0.05). The serum levels of HA, LN, PCⅢ and Ⅳ-C in the treatment group were significantly lower than those before treatment (P <0.05). After treatment, the difference between the two groups was statistically significant (P <0.05). Conclusion: Fuzhenghuayu Capsule can not only improve the clinical symptoms, signs and liver function of patients with liver cirrhosis caused by schistosomiasis, but also effectively improve liver fibrosis.